Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02274038 | Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for… | N/A | terminated | Oct 24, 2014 | University of Pennsylvania | Poor Accrual | Enrollment / accrual |
| NCT02621333 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV… | Phase 2 | terminated | Dec 3, 2015 | Henan Cancer Hospital | As there are so many clinical trials in progress and the number of patients enrolled limited. | Enrollment / accrual |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT00380666 | The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small… | N/A | withdrawn | Sep 26, 2006 | University of Aarhus | Technical problems. | Other (stated, no rule matched) |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Phase 1 / Phase 2 | withdrawn | Jan 16, 2014 | Jazz Pharmaceuticals | Protocol not activated. | Other (stated, no rule matched) |
| NCT01573338 | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together… | Phase 1 / Phase 2 | terminated | Apr 9, 2012 | Bayer | not stated | Not stated |
| NCT04835025 | Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung… | — | suspended | Apr 8, 2021 | Tongji Hospital | because of COVID-19 | COVID-19 / pandemic |
| NCT01244191 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of… | Phase 3 | terminated | Nov 19, 2010 | Daiichi Sankyo | Sponsor decision due to the protocol-defined stopping boundary for futility was met based on the… | Efficacy / futility |
| NCT04069442 | cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving…(LUNG-PREDICT) | — | withdrawn | Aug 28, 2019 | University Hospital, Grenoble | access to human body samples by another existing cohort | Other (stated, no rule matched) |
| NCT01237171 | A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non… | — | withdrawn | Nov 9, 2010 | IsoRay Medical, Inc. | Study never moved past ideation phase | Other (stated, no rule matched) |
| NCT03644823 | Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced…(COM-IT-1) | Phase 2 | terminated | Aug 23, 2018 | Oslo University Hospital | slow recruiting | Enrollment / accrual |
| NCT02608528 | Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response… | — | terminated | Nov 18, 2015 | Abramson Cancer Center at Penn Medicine | Poor Accrual | Enrollment / accrual |
| NCT02722369 | STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus… | Phase 2 | terminated | Mar 30, 2016 | University College, London | Low recruitment, lack of efficacy and increased adverse events in investigational arm. | Safety / toxicity |
| NCT02132598 | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | Phase 2 | terminated | May 7, 2014 | Liza Villaruz, MD | Trial stopped due to slow patient accrual. | Enrollment / accrual |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | Phase 1 / Phase 2 | withdrawn | Sep 10, 2020 | Virginia Commonwealth University | AbbVie decided to stop trial involving Venetoclax for safety measures needed | Safety / toxicity |
| NCT01212627 | Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer | Phase 1 | terminated | Sep 30, 2010 | Angela Taber MD | Determination to stop enrollment made due to funding | Enrollment / accrual |
| NCT04274907 | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult… | Phase 1 | terminated | Feb 18, 2020 | AbbVie | Company Decision | Sponsor / business decision |
| NCT02400424 | Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor(GFPC_01-14) | N/A | terminated | Mar 27, 2015 | Centre Leon Berard | Approval of adjuvant durvalumab after RT-CT (not anticipated in the study design) and small number… | Other (stated, no rule matched) |
| NCT03256721 | Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment… | Phase 2 | terminated | Aug 22, 2017 | Fuzhou General Hospital | Due to the enrollment was slow and exceeded the expected enrollment time | Enrollment / accrual |
| NCT04267237 | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus… | Phase 2 | withdrawn | Feb 12, 2020 | Hoffmann-La Roche | Accrual timelines | Enrollment / accrual |
| NCT02893332 | Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung…(Sindas) | Phase 3 | terminated | Sep 8, 2016 | Sichuan Provincial People's Hospital | After interim analysis, IRB recommend termination. | Efficacy / futility |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth… | Phase 1 | terminated | Apr 24, 2017 | ADC Therapeutics S.A. | Safety | Safety / toxicity |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons. | Safety / toxicity |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade… | Phase 2 | withdrawn | Apr 3, 2019 | Ochsner Health System | Lack of accrual | Enrollment / accrual |
| NCT02262000 | Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer(SABR) | N/A | terminated | Oct 10, 2014 | West Virginia University | Investigator left institution | Investigator |
| NCT02485652 | Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive… | Phase 2 | terminated | Jun 30, 2015 | Hanmi Pharmaceutical Company Limited | Study termination by the Sponsor | Other (stated, no rule matched) |
| NCT03382899 | Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone…(Cypress 1) | Phase 2 | terminated | Dec 26, 2017 | Eli Lilly and Company | The CYPRESS-1 trial was closed early after the planned primary analysis because the risk benefit… | Other (stated, no rule matched) |
| NCT04170959 | The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC(RADFORMIN) | Phase 2 | terminated | Nov 20, 2019 | ethisch.comite@uza.be | Loss of external funding | Funding |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on… | Phase 2 | terminated | Sep 26, 2008 | Hoffmann-La Roche | The study was terminated due to the termination of the clinical development program. | Other (stated, no rule matched) |
| NCT00662597 | ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment…(ATRACT-1) | Phase 3 | terminated | Apr 21, 2008 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00738387 | A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for…(ATTRACT-2) | Phase 3 | terminated | Aug 20, 2008 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced… | Phase 1 / Phase 2 | terminated | Dec 29, 2010 | MedImmune LLC | In conjunction with the overall risk-benefit assessment, study was terminated prematurely due to… | Safety / toxicity |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients… | Phase 3 | terminated | May 30, 2007 | GlaxoSmithKline | The study was terminated following assessment of the lack of efficacy of the study product by the… | Efficacy / futility |
| NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based… | Phase 3 | terminated | May 4, 2018 | Zai Lab (Shanghai) Co., Ltd. | As the treatment model of extensive-stage small cell lung cancer changed rapidly and the enrollment… | Enrollment / accrual |
| NCT03603652 | NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of… | N/A | terminated | Jul 27, 2018 | Ethicon, Inc. | Study originally suspended pending a protocol amendment but study now terminated. | Other (stated, no rule matched) |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | Phase 1 | terminated | Aug 11, 2017 | National Health Research Institutes, Taiwan | No more funding | Funding |
| NCT04576208 | A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related… | Phase 2 | withdrawn | Oct 6, 2020 | Takeda | Business Decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in… | Phase 1 / Phase 2 | terminated | Nov 20, 2008 | Regeneron Pharmaceuticals | not stated | Not stated |
| NCT04460729 | A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14… | Phase 2 | withdrawn | Jul 8, 2020 | Novartis Pharmaceuticals | company decision | Sponsor / business decision |
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received…(PIONEER) | Phase 3 | terminated | Dec 26, 2005 | CTI BioPharma | not stated | Not stated |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC…(N3) | Phase 1 / Phase 2 | withdrawn | Dec 4, 2017 | Royal Marsden NHS Foundation Trust | Withdrawal of financial support from funder | Funding |
| NCT04267913 | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care… | Phase 2 | withdrawn | Feb 13, 2020 | SWOG Cancer Research Network | The pharmaceutical company sold the compound and pulled out. | Sponsor / business decision |
| NCT03553550 | Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected…(LIBERTI) | — | terminated | Jun 12, 2018 | Addario Lung Cancer Medical Institute | Enrollment futility | Efficacy / futility |
| NCT02762877 | Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma… | — | terminated | May 5, 2016 | Genomic Health®, Inc. | Business decision | Sponsor / business decision |
| NCT04044170 | Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Phase 2 | terminated | Aug 5, 2019 | Hanmi Pharmaceutical Company Limited | Study termination by the Sponsor | Other (stated, no rule matched) |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer…(DOMINATION) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab…(DOME) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT02109653 | Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant… | Phase 2 | withdrawn | Apr 10, 2014 | Array Biopharma, now a wholly owned subsidiary of Pfizer | Study never started - transferred to Array. | Other (stated, no rule matched) |
| NCT03699033 | Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung… | Phase 2 | withdrawn | Oct 9, 2018 | Stephanie Smiddy | No patients available | Other (stated, no rule matched) |
| NCT03302247 | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | Phase 2 | terminated | Oct 5, 2017 | Fox Chase Cancer Center | Unable to accrue subjects | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 12, 2021source: clinicaltrials